Zip Bio
Compressing Biology to Develop the Next Generation of Therapies
Company Overview
Snapshot
Founded in April 2023 by Roee Farber and Ori Zelichov, Zip Bio operates with 1–10 employees. The company has raised $4 million across one funding round from two investors. In September 2024, Zip Bio secured seed funding, with NFX Capital participating.
Business overview
Zip Bio is a Health Tech & Life Sciences company focused on revolutionizing therapeutic development through generative artificial intelligence. The company's core technology involves creating de novo genes and proteins to distill complex functions into compact, highly effective therapeutic molecules. Zip Bio addresses unmet medical needs by serving the pharmaceutical and life sciences industries, operating within the Drugs Discovery & Development sector.
Strategic signal
In September 2024, Zip Bio raised $4 million in seed funding, highlighting investor confidence in its AI-driven approach to therapeutic development. This capital infusion signals a critical validation of the company's technology and its potential to accelerate the creation of novel medicines, positioning Zip Bio for rapid advancement in the competitive biotech landscape.
Log in to access full profile ›Company Intelligence Q&A
- When was Zip Bio founded?
- Zip Bio was founded in April 2023 by Roee Farber and Ori Zelichov.
- What is Zip Bio's primary focus?
- Zip Bio primarily focuses on utilizing generative artificial intelligence to develop next-generation therapeutics by creating de novo genes and proteins, aiming to address unmet medical needs.
- How much capital has Zip Bio raised to date?
- Zip Bio has raised a total of $4 million in funding.
- Which investors participated in Zip Bio's seed funding round?
- In September 2024, Zip Bio secured seed funding with participation from.
- What is the employee count at Zip Bio?
- Zip Bio currently has 1–10 employees.